340B Program Is Driving Up Costs and Needs Urgent Reform | AMCP Annual 2025
April 7th 2025At the 2025 AMCP annual meeting in Houston from March 31 to April 3, John M. O'Brien, Pharm.D., MPH, president and CEO of the National Pharmaceutical Council (NPC), shared concerns and potential reforms in a conversation with Managed Healthcare Executive.
Read More
GLP-1 and Biosimilars Trends, Impact on Payers and Costs | AMCP Annual 2025
April 4th 2025Doug Long, BA, MBA, vice president of Industry Relations at IQVIA, shares what's happening in the growing GLP-1 and biosimilars space. Long was a presenter at the annual AMCP 2025 meeting in Houston, where he discussed these topics and more earlier this week.
Read More
The Future of Gene Therapies and Their Impact on Payers | AMCP Annual 2025
April 3rd 2025Maria Lowe, Ph.D., associate vice president of Pharmaceutical Intelligence at Institute for Clinical and Economic Review (ICER) addresses the possible gene therapies that we could see reach the market this year.
Read More
Defining Specialty Drugs and Upcoming Approvals to Watch | AMCP Annual 2025
April 3rd 2025Maria Lowe, Pharm.D., BCPS, associate vice president of pharmaceutical intelligence at the Institute for Clinical and Economic Review, described specialty drugs as high-cost treatments requiring complex handling or disease management and highlighted key upcoming approvals, including a new PCSK9 inhibitor for lipid lowering and tolebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, which could become the first in its class approved for multiple sclerosis.
Read More
Evidence Suggests IRA is a ‘Poorly Designed Policy’ | AMCP Annual 2025
April 3rd 2025Julie Patterson, Pharm.D., Ph.D., of the National Pharmaceutical Council, tells Managed Healthcare Executive at the annual AMCP meeting in Houston that the Inflation Reduction Act of 2022 is a policy that seems to be leading to more consequences than it is benefits.
Read More
Impact of IRA Drug Negotiation on Part D Formularies and PBMs | AMCP Annual 2025
April 3rd 2025At the AMCP 2025 meeting, Julie Patterson, Pharm.D., Ph.D., of the National Pharmaceutical Council, explained that the impact of the IRA drug negotiation program on patient access is still unclear, but early research shows that coverage for selected drugs has been strong. However, as Medicare Part D undergoes changes, there are concerns about how plan incentives, formulary design and utilization management might affect future access.
Read More
What's Ahead for Site-Neutral Payments in Medicare and State Policies | AMCP Annual 2025
April 2nd 2025Co-presenter, Sean Shirk, Pharm.D., director of specialty clinical solutions at Prime Therapeutics, discussed this topic during a presentation on legislative impacts on site of service at the AMCP 2025 annual meeting in Houston on Tuesday.
Read More
Winrevair Shows Promise in Advancing PAH Treatment | ACC 2025
March 31st 2025Marc Humbert, M.D., Ph.D., professor of respiratory medicine at Université Paris-Saclay and Inserm, believes that recent clinical trials have reinforced the potential of Winrevair (sotatercept) as a breakthrough in pulmonary arterial hypertension (PAH) treatment.
Read More
Medicaid Cuts Remain Center Stage as Experts Address Industry Challenges
March 28th 2025In a recent conversation with Jennifer McGuigan Babcock, senior vice president for Medicaid policy at the Association for Community Affiliated Plans (ACAP), and Gabe Scott, a partner at K&L Gates Health Care Group, the two discussed efforts to protect Medicaid’s role in the healthcare system and the consequences of the budget cuts announced in February.
Read More
Medicare Costs Rise in 2025 With Higher Part D Premiums, Advantage Deductibles
March 27th 2025During last year’s enrollment period, millions of Medicare beneficiaries reviewed their coverage options and selected new Medicare plans for the 2025 calendar year due to changes including the plans being offered, increases in premiums and more, according to an eHealth analysis.
Read More
Is Journavx a Step Forward In Pain Management or a Repeat of Past Mistakes?
March 25th 2025In a Q&A with Josef Witt-Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares the potential benefits and risks of the alternative non-opioid pain medication, expressing that while it could help cut down on opioid use, its long-term impact is unclear.
Read More
Increased Risk of Severe RSV Illness in Adults With Asthma or COPD
March 19th 2025Historically, RSV has been studied mainly in infants and older adults, but recent research shows that it also poses a significant threat to adults with asthma and COPD. However, research on the virus within these groups has been limited.
Read More
What Medicaid Cuts Could Mean for Healthcare Access and Hospital Stability
March 17th 2025Jennifer McGuigan Babcock, senior vice president for Medicaid policy at the Association for Community Affiliated Plans (ACAP), and Gabe Scott, a partner at K&L Gates Health Care Group, spoke with Managed Healthcare Executive about what these cuts could mean for the healthcare system.
Read More
Where Are They Now? Lissy Hu Joins Ascend to Tackle Workforce Challenges
March 14th 2025Lissy Hu, M.D., MBA, CEO of Ascend Learning, was one of Managed Healthcare Executive’s 2022 Emerging Leaders in Healthcare winners. The editors caught up with Hu as part of our new “Where Are They Now?” series spotlighting the career paths of past emerging leaders.
Read More
Leadership Team at The Cigna Group Revamps in Efforts to Drive Growth, Enhance Customer Focus
March 14th 2025David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
Read More